Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
3.
Arch Dermatol Res ; 315(5): 1429-1433, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36416979

ABSTRACT

It is well established that immunosuppressed patients are at increased risk for poor outcomes (PO) from cutaneous squamous cell carcinoma (cSCC), including local recurrence (LR), nodal metastasis (NM), distant metastasis (DM), and disease-specific death (DSD). Defining PO risk is challenging but may be beneficial in guiding management. We aimed to define PO risk factors and evaluated their importance in immunosuppressed versus immunocompetent patients. We conducted a 4-year single-center retrospective review of patients with cSCC. Patient and tumor characteristics were evaluated in those that experienced PO. Immunosuppressed patients were ~ 11-fold more likely than immunocompetent patients to develop PO (10/85 vs. 15/1332, p < 0.0001). Among those with PO, immunosuppressed patients had diminished relapse free (p = 0.026) and progression free (p < 0.001) survival compared to immunocompetent. Immunosuppression was significantly associated with LR (p < 0.00001). Immunosuppressed patients were also more likely to develop NM, DM and experience DSD (p = 0.027). Mohs Appropriate Use Criteria was associated with NM, DM and DSD (p = 0.029), with area H tumors more likely to result in metastasis and death. In conclusion, immunosuppressed patients are more likely to develop LR, metastasis, and DSD from cSCC compared to immunocompetent patients. Immunosuppressed status was an independent risk factor for PO in this cohort and further considered for its inclusion in prognostication schema is warranted.


Subject(s)
Carcinoma, Squamous Cell , Skin Neoplasms , Humans , Carcinoma, Squamous Cell/pathology , Skin Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Immunocompromised Host , Retrospective Studies , Neoplasm Staging
5.
Skin Appendage Disord ; 5(5): 304-308, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31559255

ABSTRACT

Dermatophytomas represent a historically difficult-to-treat complication of onychomycosis and are characterized by adherent fungal masses encased in biofilm in the subungual space. In this study, we evaluated the efficacy of 10% efinaconazole solution in patients with onychomycosis complicated by dermatophytomas. Cure was achieved in 65% of target great toenails. All dermatophytomas resolved and did not recur during the study. The median time to dermatophytoma resolution was 16 weeks.

7.
Skin Appendage Disord ; 5(2): 108-110, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30815445

ABSTRACT

Lichen planopilaris (LPP) is a scarring alopecia seen classically in older Caucasian women. Frontal fibrosing alopecia (FFA) is a distinct disease that shares the histologic and trichoscopic features of LPP but differs in its clinical presentation in that it involves the frontal scalp and occasionally the eyelashes and eyebrows of older Caucasian women. Several recent studies have described a link between FFA and the use of sunscreen. Here we report a case of LPP arising in the part line of the scalp of a woman with a history of long-term daily application of spray-on sunscreen to the hair part line.

8.
J Drugs Dermatol ; 17(3): 364-367, 2018 Mar 01.
Article in English | MEDLINE | ID: mdl-29537456

ABSTRACT

Local adverse reactions to vaccination are typically mild and often quickly resolve. Vaccine adjuvants such as aluminum salts in combination with improper vaccination technique may result in severe local adverse reactions. As far as we know, there is only one prior case of frankly necrotic rapidly progressing vaccine site necrosis, which occurred in a pediatric patient.1 To our knowledge, this is the first adult case of vaccine site necrosis to be reported. The presumed etiology has been aluminum salt adjuvants and improper vaccination technique. Here we present an adult case of a severe local reaction to a vaccine resulting in necrosis of the epidermis and dermis with central ulceration. Skin appendages were also involved, with necrosis of eccrine coils and hair follicles. This necrotic ulceration was likely due to robust inflammatory response to aluminum salt subcutaneous injection. Correct vaccine placement, needle size, and needle length may reduce adverse local skin reactions.

J Drugs Dermatol. 2018;17(3):364-367.

.


Subject(s)
Injection Site Reaction/diagnosis , Skin Ulcer/diagnosis , Vaccination/adverse effects , Female , Humans , Injection Site Reaction/therapy , Middle Aged , Necrosis/therapy , Vaccination/trends
9.
Int J Dermatol ; 57(5): 515-520, 2018 May.
Article in English | MEDLINE | ID: mdl-29057463

ABSTRACT

Anaplastic large cell lymphoma (ALCL) limited to the skin is a distinct disease that is designated primary cutaneous ALCL (pcALCL). It has an indolent course with a significantly better prognosis compared to systemic ALCL (sALCL). Anaplastic lymphoma kinase (ALK) expression in lesions of cutaneous ALCL is classically considered to be a marker for skin involvement by sALCL. However, recent reports of patients with ALK-positive pcALCL challenge this concept and raise prognostic and therapeutic dilemmas. Herein, we report a case of ALK-positive pcALCL in a 45-year-old woman who was treated with local radiotherapy. We review previously reported cases in the literature to better characterize this rare variant. Overall, the rates of cutaneous recurrence, systemic dissemination, and disease-related mortality in ALK-positive pcALCL do not differ from those previously reported in pcALCL. ALK-positive pcALCL is diagnosed at younger age and has a better disease course in children compared to adults with lower incidences of skin recurrence and progression to systemic disease. We conclude that ALK-positivity in cutaneous ALCL does not necessarily imply systemic disease. ALK-positive pcALCL has an excellent prognosis and should be treated by excision and/or radiotherapy. However, patients must remain under close long-term follow-up as recurrence and progression to systemic disease may occur.


Subject(s)
Lymphoma, Primary Cutaneous Anaplastic Large Cell/pathology , Lymphoma, Primary Cutaneous Anaplastic Large Cell/radiotherapy , Skin Neoplasms/pathology , Skin Neoplasms/radiotherapy , Biopsy, Needle , Disease-Free Survival , Female , Follow-Up Studies , Humans , Immunohistochemistry , Lymphoma, Primary Cutaneous Anaplastic Large Cell/diagnosis , Lymphoma, Primary Cutaneous Anaplastic Large Cell/mortality , Male , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Staging , Risk Assessment , Skin Neoplasms/diagnosis , Skin Neoplasms/mortality , Survival Analysis , Treatment Outcome
10.
Skin Appendage Disord ; 5(1): 9-12, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30643774

ABSTRACT

BACKGROUND: Topical efinaconazole 10% solution is a promising new treatment for distal lateral subungual onychomycosis (DLSO). However, it is unknown whether this treatment is both compatible and efficacious in individuals wearing toenail polish. MATERIALS AND METHODS: We evaluated the efficacy and compatibility of efinaconazole 10% solution with concurrent nail polish use in treating DLSO over 52 weeks. Efficacy was assessed using the onychomycosis severity index (OSI) and by measuring nail growth and thickness, while compatibility with nail polish was evaluated with questionnaires. RESULTS: Eleven patients completed the study; 6 wore nail polish regularly and 5 abstained from polish. The efficacy of efinaconazole was not diminished by concurrent nail polish use as measured by OSI, nail growth, and thickness. However, this treatment produced undesirable cosmetic changes to the quality of nail polish over time. CONCLUSIONS: While efinaconazole 10% solution is an effective treatment of DLSO in patients wearing nail polish, this treatment may diminish the quality of the polish. Further research and development is needed to enhance the compatibility of topical onychomycosis treatments with nail polish use.

11.
Skin Appendage Disord ; 5(1): 50-51, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30643782
12.
Photodiagnosis Photodyn Ther ; 18: 257-259, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28373119

ABSTRACT

Treating skin cancers and extensive actinic keratosis in patients with bullous pemphigoid (BP) can be challenging. Treatment options pose unique risks in these patients as surgical wounds can have delayed wound healing and photodynamic therapy (PDT) may exacerbate their blistering disease. We report the successful use of PDT to treat actinic keratosis and skin cancers in two patients with BP, both of whom had excellent response to PDT and tolerated treatment without any bullous disease flares. Carefully selected patients with skin cancers and stable, well controlled BP can be safely considered for treatment using PDT.


Subject(s)
Aminolevulinic Acid/administration & dosage , Aminolevulinic Acid/therapeutic use , Carcinoma, Basal Cell/drug therapy , Keratosis, Actinic/drug therapy , Pemphigoid, Bullous/drug therapy , Photochemotherapy/methods , Skin Neoplasms/drug therapy , Administration, Cutaneous , Aged , Carcinoma, Basal Cell/complications , Carcinoma, Basal Cell/pathology , Dose-Response Relationship, Drug , Humans , Keratosis, Actinic/complications , Keratosis, Actinic/pathology , Male , Pemphigoid, Bullous/complications , Pemphigoid, Bullous/pathology , Photosensitizing Agents/administration & dosage , Skin Neoplasms/complications , Skin Neoplasms/pathology , Treatment Outcome
13.
Dermatol Ther (Heidelb) ; 6(4): 555-578, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27541148

ABSTRACT

Acne is a very common non-infectious skin condition that is frequently treated in dermatological practices. Because acne is often chronic and may persist for years, safe and effective long-term maintenance therapy is often required. Given the increasing frequency of antibiotic-resistant bacteria and the gravity of the consequences of this trend, it behooves dermatologists to maximize use of non-antimicrobial therapy when treating acne. In this review of the literature we present data regarding the efficacy and appropriate use of non-antimicrobial treatments for acne. A variety of topical and oral treatment options exist that can be used in a step-wise manner according to the patients' severity and therapeutic response. Non-antimicrobial treatments can be highly efficacious at controlling acne, especially when used as maintenance therapy. While antibiotics have a role in acne treatment, they should not be used as monotherapy, and lengthy courses of antibiotic use are discouraged.

14.
Nurse Pract ; 41(4): 24-9; quiz 29-30, 2016 Apr 17.
Article in English | MEDLINE | ID: mdl-26974049

ABSTRACT

Melanoma is a malignant tumor that is usually cutaneous in origin and is associated with significant morbidity and mortality. As one of the most common cancers seen in young adults, melanoma represents a major public health concern in terms of years of lost productivity.


Subject(s)
Melanoma/diagnosis , Melanoma/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Humans , Nurse Practitioners , Nursing Diagnosis , Risk Factors , Watchful Waiting
15.
Am J Clin Dermatol ; 17(1): 33-47, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26649440

ABSTRACT

Our ability to successfully treat patients with moderate to severe psoriasis has improved significantly over the last several years with the development of more targeted therapies. IL-17A, a member of the IL-17 family of interleukins, is involved in regulating the innate and adaptive immune systems and has been identified as a key cytokine involved in the pathogenesis of psoriasis and psoriatic arthritis. In this review, we summarize our understanding of IL-17 and its role in psoriasis and psoriatic arthritis, as well as key findings from clinical trials using anti-IL-17 medications for the treatment of the aforementioned diseases. Secukinumab, ixekizumab, and brodalumab are three anti-IL-17 medications used for treating psoriasis, of which only secukinumab is FDA approved; ixekizumab and brodalumab remain under clinical development. Results from clinical trials show that these three medications are highly effective in treating psoriasis and appear to be as safe as other biologic treatments that are FDA approved.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal/therapeutic use , Interleukin-17/antagonists & inhibitors , Psoriasis/drug therapy , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Arthritis, Psoriatic/drug therapy , Biological Products/adverse effects , Biological Products/therapeutic use , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Humans , Interleukin-17/metabolism , Molecular Targeted Therapy , Signal Transduction
16.
J Drugs Dermatol ; 14(10 Suppl): s42-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26461834

ABSTRACT

Tinea pedis is a frequently encountered dermatophytosis affecting the superficial skin of the feet, primarily of adults. The prevalence of tinea pedis has increased over the last several decades due to an increase in multiple risk factors. Infection from dermatophytes is most common, but infection from other fungi can also result in tinea pedis. Four distinct clinical presentations occur: interdigital, moccasin, vesicular, and acute ulcerative types. A variety of physical exam findings can help the clinician identify patients with tinea pedis.


Subject(s)
Antifungal Agents/therapeutic use , Tinea Pedis/diagnosis , Tinea/diagnosis , Antifungal Agents/administration & dosage , Foot/microbiology , Humans , Prevalence , Tinea/drug therapy , Tinea/epidemiology , Tinea/microbiology , Tinea Pedis/drug therapy , Tinea Pedis/epidemiology
18.
J Drugs Dermatol ; 14(5): 524-6, 2015 May.
Article in English | MEDLINE | ID: mdl-25942674

ABSTRACT

Onychomycosis is a common fungal infection of the nail unit that results in discoloration, subungual debris, thickening, onycholysis, and often pain and impairment of mobility. Dermatophytomas are characterized by a thick fungal mass within and under the nail plate and are especially resistant to treatment. Here we report a case of a patient with a dermatophytoma who had failed oral terbinafine but was successfully treated with efinaconazole 10% topical solution.


Subject(s)
Antifungal Agents/administration & dosage , Foot Dermatoses/drug therapy , Onychomycosis/drug therapy , Triazoles/administration & dosage , Administration, Topical , Aged , Antifungal Agents/therapeutic use , Foot Dermatoses/microbiology , Foot Dermatoses/pathology , Humans , Male , Naphthalenes/administration & dosage , Naphthalenes/therapeutic use , Onychomycosis/microbiology , Onychomycosis/pathology , Terbinafine , Tinea/drug therapy , Tinea/pathology , Treatment Outcome , Triazoles/therapeutic use
19.
J Am Acad Dermatol ; 72(2): 239-45, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25592340

ABSTRACT

BACKGROUND: Mycoplasma pneumoniae infection is associated with extrapulmonary complications, including mucocutaneous eruptions. These eruptions, which have been termed either "Stevens-Johnson syndrome" or "erythema multiforme" in the literature, may differ from drug-induced Stevens-Johnson syndrome or viral-associated erythema multiforme. OBJECTIVE: We sought to review the literature characterizing morphology and disease course of M pneumoniae-associated mucocutaneous disease. METHODS: A comprehensive literature search identified 95 articles with 202 cases. RESULTS: Patients were often young (mean age: 11.9 years) and male (66%). Cutaneous involvement ranged from absent (34%), to sparse (47%), to moderate (19%). Oral, ocular, and urogenital mucositis was reported in 94%, 82%, and 63% of cases, respectively. Treatments included antibiotics (80%), systemic corticosteroids (35%), supportive care alone (8%), and/or intravenous immunoglobulin (8%). Complications included mucosal damage (10%), cutaneous scarring (5.6%), recurrence (8%), and mortality (3%). LIMITATIONS: Mild cases may not have been published; thus this review may have a bias toward more severe disease. CONCLUSION: M pneumoniae-associated mucocutaneous disease has prominent mucositis and sparse cutaneous involvement, although cutaneous involvement varies. Because of the distinct morphology, mild disease course, and potentially important clinical implications regarding treatment, we propose a revision of the nomenclature system and suggest the term "Mycoplasma-induced rash and mucositis" for these cases.


Subject(s)
Exanthema/diagnosis , Exanthema/microbiology , Mucositis/microbiology , Mycoplasma Infections/diagnosis , Mycoplasma pneumoniae/isolation & purification , Adrenal Cortex Hormones/therapeutic use , Age Distribution , Anti-Bacterial Agents/therapeutic use , Child , Diagnosis, Differential , Erythema Multiforme/diagnosis , Exanthema/drug therapy , Female , Humans , Immunoglobulins, Intravenous/therapeutic use , Male , Mucositis/drug therapy , Mycoplasma Infections/drug therapy , Sex Distribution , Stevens-Johnson Syndrome/diagnosis , Syndrome , Treatment Outcome
20.
Skin Appendage Disord ; 1(1): 38-42, 2015 Mar.
Article in English | MEDLINE | ID: mdl-27172289

ABSTRACT

Leukonychia totalis and leukonychia partialis are rare nail findings characterized by complete or partial whitening of the nail plate. Leukonychia totalis and leukonychia partialis are usually inherited or associated with systemic disease. Here, we report the case of a 25-year-old man with idiopathic acquired leukonychia totalis and leukonychia partialis and review the literature on this topic.

SELECTION OF CITATIONS
SEARCH DETAIL
...